Association of Low B Cell Count and IgG Levels with Infection, and Poor Vaccine Response with All-Cause Mortality in an Immunosuppressed Vasculitis Population

Arthritis Care and Research

Volumn 68, Issue 6, 2016, Pages 853-860

  Morgan, Matthew David ^a   Richter, Alex ^a   Al Ali, Samer ^a   Flint, Julia ^a   Yiannakis, Constantina ^a   Drayson, Mark ^a   Goldblatt, David ^b   Harper, Lorraine ^a  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CD16 ANTIGEN; CD19 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; HAEMOPHILUS INFLUENZAE TYPE B MENINGOCOCCUS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS INFLUENZAE VACCINE; IMMUNOGLOBULIN G; MENINGOCOCCUS VACCINE; MYCOPHENOLIC ACID; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; PREDNISOLONE; RITUXIMAB; STEROID; UNCLASSIFIED DRUG; W135 VACCINE; INFLUENZA VACCINE; VACCINE;

ADULT; AGE; AGED; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BACTEREMIA; BACTERIAL INFECTION; CAUSE OF DEATH; CD3+ T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG RESPONSE; EOSINOPHILIC GRANULOMA; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL INFECTION; HERPES ZOSTER; HUMAN; HUMORAL IMMUNITY; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFECTION RATE; INFLUENZA B; KIDNEY DYSFUNCTION; LEUKOCYTE COUNT; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; LYMPHOCYTE SUBPOPULATION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC POLYANGIITIS; MORTALITY; MUCOSAL DISEASE; MYCOSIS; NEOPLASM; OSTEOMYELITIS; PERITONITIS; PNEUMOCOCCAL INFECTION; PNEUMOCOCCAL MENINGITIS; POLYARTERITIS NODOSA; PREDICTOR VARIABLE; RELAPSE; REMISSION; RISK FACTOR; SKIN INFECTION; SYSTEMIC VASCULITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VACCINATION; VIRUS INFECTION; WEGENER GRANULOMATOSIS; COHORT ANALYSIS; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; MIDDLE AGED;

AGED; B-LYMPHOCYTES; COHORT STUDIES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOGLOBULIN G; INFECTION; INFLUENZA VACCINES; LYMPHOCYTE COUNT; MALE; MENINGOCOCCAL VACCINES; MIDDLE AGED; PNEUMOCOCCAL VACCINES; SYSTEMIC VASCULITIS; VACCINATION; VACCINES;

EID: 84970006293     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.22757     Document Type: Article

References (27)

1. Flossmann O, Berden A, de Groot K, Hagen C, Harper L, Heijl C, et al., Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 2011; 70: 488-94.
2. Little MA, Nightingale P, Verburgh CA, Hauser T, de Groot K, Savage C, et al., Early mortality in systemic vasculitis: relative contribution of adverse events and active vasculitis. Ann Rheum Dis 2010; 69: 1036-43.
3. Wotton CJ, Goldacre MJ., Risk of invasive pneumococcal disease in people admitted to hospital with selected immune-mediated diseases: record linkage cohort analyses. J Epidemiol Community Health 2012; 66: 1177-81.
4. Charlier C, Henegar C, Launay O, Pagnoux C, Berezne A, Bienvenu B, et al., Risk factors for major infections in Wegener granulomatosis: analysis of 113 patients. Ann Rheum Dis 2009; 68: 658-63.
5. Wall N, Harper L., Complications of long-term therapy for ANCA-associated systemic vasculitis. Nat Rev Nephrol 2012; 8: 523-32.
6. Saad CG, Borba EF, Aikawa NE, Silva CA, Pereira RM, Calich AL, et al., Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Ann Rheum Dis 2011; 70: 1068-73.
7. Whitelegg AM, Birtwistle J, Richter A, Campbell JP, Turner JE, Ahmed TM, et al., Measurement of antibodies to pneumococcal, meningococcal and haemophilus polysaccharides, and tetanus and diphtheria toxoids using a 19-plexed assay. J Immunol Methods 2012; 377: 37-46.
8. Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M, Cohen-Tervaert JW, et al., Outcomes from studies of antineutrophil cytoplasm antibody associated vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. Ann Rheum Dis 2008; 67: 1004-10.
9. Hua C, Barnetche T, Combe B, Morel J., Effect of methotrexate, anti-tumor necrosis factor α, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2014; 66: 1016-26.
10. Holvast AS, Benne CA, Huckriede A, Wilschut JC, Palache AM, Kallenberg CG, et al., Wegener's granulomatosis patients show an adequate antibody response to influenza vaccination. Ann Rheum Dis 2009; 68: 873-8.
11. Marchand-Janssen C, Loulergue P, Mouthon L, Mahr A, Blanche P, Deforges L, et al., Patients with systemic inflammatory and autoimmune diseases are at risk of vaccine-preventable illnesses. Rheumatology (Oxford) 2011; 50: 1099-1105.
12. Abzug MJ, Song LY, Levin MJ, Nachman SA, Borkowsky W, Pelton SI., Antibody persistence and immunologic memory after sequential pneumococcal conjugate and polysaccharide vaccination in HIV-infected children on highly active antitertroviral therapy. Vaccine 2013; 31: 4782-90.
13. Kostianovsky A, Charles P, Alves JF, Goulet M, Pagnoux C, Le Guern V, et al., Immunogenicity and safety of seasonal and 2009 pandemic A/H1N1 influenza vaccines for patients with autoimmune diseases: a prospective, monocentre trial on 199 patients. Clin Exp Rheumatol 2012; 30 Suppl 70: S83-9.
14. Stassen PM, Sanders JS, Kallenberg CG, Stegeman CA., Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis. Nephrol Dial Transplant 2008; 23: 654-8.
15. Zycinska K, Romanowska M, Nowak I, Rybicka K, Wardyn KA, Brydak LB., Antibody response to inactivated subunit influenza vaccine in patients with Wegener's granulomatosis. J Physiol Pharmacol 2007; 58 Suppl 5: 819-28.
16. Hedlund J, Ortqvist A, Konradsen HB, Kalin M., Recurrence of pneumonia in relation to the antibody response after pneumococcal vaccination in middle-aged and elderly adults. Scand J Infect Dis 2000; 32: 281-6.
17. Sankilampi U, Honkanen PO, Bloigu A, Leinonen M., Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J Infect Dis 1997; 176: 1100-4.
18. Kumar D, Welsh B, Siegal D, Chen MH, Humar A., Immunogenicity of pneumococcal vaccine in renal transplant recipients: three year follow-up of a randomized trial. Am J Transplant 2007; 7: 633-8.
19. Crnkic Kapetanovic M, Saxne T, Truedsson L, Geborek P., Persistence of antibody response 1.5 years after vaccination using 7-valent pneumococcal conjugate vaccine in patients with arthritis treated with different antirheumatic drugs. Arthritis Res Ther 2013; 15: R1.
20. Goupil R, Brachemi S, Nadeau-Fredette AC, Deziel C, Troyanov Y, Lavergne V, et al., Lymphopenia and treatment-related infectious complications in ANCA-associated vasculitis. Clin J Am Soc Nephrol 2013; 8: 416-23.
21. McGregor JG, Hogan SL, Hu Y, Jennette CE, Falk RJ, Nachman PH., Glucocorticoids and relapse and infection rates in anti-neutrophil cytoplasmic antibody disease. Clin J Am Soc Nephrol 2012; 7: 240-7.
22. Weidanz F, Day CJ, Hewins P, Savage CO, Harper L., Recurrences and infections during continuous immunosuppressive therapy after beginning dialysis in ANCA-associated vasculitis. Am J Kidney Dis 2007; 50: 36-46.
23. Booth AD, Almond MK, Burns A, Ellis P, Gaskin G, Neild GH, et al., Outcome of ANCA-associated renal vasculitis: a 5-year retrospective study. Am J Kidney Dis 2003; 41: 776-84.
24. De Groot K, Harper L, Jayne D, Flores Suarez L, Gregorini G, Gross W, and the European Vasculitis Study Group. Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial. Ann Intern Med 2009; 150: 670-80.
25. Moratto D, Gulino AV, Fontana S, Mori L, Pirovano S, Soresina A, et al., Combined decrease of defined B and T cell subsets in a group of common variable immunodeficiency patients. Clin Immunol 2006; 121: 203-14.
26. Goldacker S, Draeger R, Warnatz K, Huzly D, Salzer U, Thiel J, et al., Active vaccination in patients with common variable immunodeficiency (CVID). Clin Immunol 2007; 124: 294-303.
27. Paquin-Proulx D, Santos BA, Carvalho KI, Toledo-Barros M, Barreto de Oliveira AK, Kokron CM, et al., IVIg immune reconstitution treatment alleviates the state of persistent immune activation and suppressed CD4 T cell counts in CVID. PLoS One 2013; 8: e75199.